Loading...
SCYX logo

SCYNEXIS, Inc.NasdaqCM:SCYX Rapport sur les actions

Capitalisation boursière US$58.1m
Prix de l'action
US$0.73
US$4.19
82.6% sous-évalué décote intrinsèque
1Y0.2%
7D11.3%
1D
Valeur du portefeuille
​
Voir

SCYNEXIS, Inc.

NasdaqCM:SCYX Rapport sur les actions

Capitalisation boursière : US$58.1m

SCYNEXIS (SCYX) Aperçu de l'action

SCYNEXIS, Inc. est une société de biotechnologie qui se consacre au développement de médicaments pour le traitement et la prévention des infections fongiques difficiles à traiter et résistantes aux médicaments aux États-Unis. Plus de détails

SCYX analyse fondamentale
Score flocon de neige
Évaluation3/6
Croissance future1/6
Performances passées0/6
Santé financière6/6
Dividendes0/6

Récompenses

Les revenus devraient augmenter 18.49% par an

Les revenus ont augmenté 19.1% par an au cours des 5 dernières années

Se négocie à un bon prix par rapport à ses pairs et au secteur

Analyse des risques

Les actionnaires ont été considérablement dilués au cours de l'année écoulée

Les bénéfices devraient diminuer en moyenne de 3.9% par an au cours des 3 prochaines années

Actuellement non rentable et ne devrait pas le devenir au cours des 3 prochaines années

N'a pas de capitalisation boursière significative ( $58M )


SCYX Community Fair Values

Create Narrative

See what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

SCYNEXIS, Inc. Concurrents

Historique des prix et performances

Résumé des hausses, des baisses et des variations du cours de l'action pour la période du 1er janvier au 31 décembre 2009 SCYNEXIS
Historique des cours de bourse
Prix actuel de l'actionUS$0.73
Plus haut sur 52 semainesUS$1.31
Plus bas sur 52 semainesUS$0.56
Bêta1.12
Variation sur 1 mois-28.30%
Variation sur 3 mois3.00%
Variation sur 1 an0.18%
Variation sur 3 ans-70.98%
Variation sur 5 ans-92.66%
Évolution depuis l'introduction en bourse-99.19%

Nouvelles et mises à jour récentes

Recent updates

Article d’analyse • Jan 23

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Sep 09

Can SCYNEXIS (NASDAQ:SCYX) Afford To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Article d’analyse • May 17

Here's Why SCYNEXIS (NASDAQ:SCYX) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Article d’analyse • Aug 08

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Article d’analyse • Jun 19

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) 32% Price Drop

The SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price has softened a substantial 32% over the previous 30 days, handing back...
Article d’analyse • May 12

SCYNEXIS, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

It's been a good week for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, because the company has just released its latest...
Article d’analyse • Apr 04

SCYNEXIS (NASDAQ:SCYX) Seems To Use Debt Rather Sparingly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Seeking Alpha • Apr 02

Scynexis: Update Following Restructuring Of GSK Deal

Summary Scynexis stock price has resumed the downtrend following a restructuring of the GSK deal associated with considerable reduction of pending milestones. SCYX ended 2023 with $98M, but is still trading at a $54M market cap. Cash runway is beyond 2 years, not accounting for pending milestones. Just the milestones from delivery of readouts to GSK and resumption and progress of MARIO trial are expected to cover all 2024 operating expenses. SCYX stock is undervalued in the short/medium term, but its long-term success is unclear considering emerging competition and pipeline limited to SCY-247. Read the full article on Seeking Alpha
Article d’analyse • Feb 01

Lacklustre Performance Is Driving SCYNEXIS, Inc.'s (NASDAQ:SCYX) Low P/S

With a price-to-sales (or "P/S") ratio of 0.6x SCYNEXIS, Inc. ( NASDAQ:SCYX ) may be sending very bullish signals at...
Article d’analyse • Dec 21

Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Article d’analyse • Sep 26

Little Excitement Around SCYNEXIS, Inc.'s (NASDAQ:SCYX) Revenues As Shares Take 28% Pounding

SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares have had a horrible month, losing 28% after a relatively good period beforehand...
Article d’analyse • Aug 17

Is SCYNEXIS (NASDAQ:SCYX) Using Too Much Debt?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Aug 26

Scynexis: Uninvestible At This Point, Downgrading To A Sell Rating

Summary SCYX has a commercial antifungal Brexafemme. However, we are neutral on its commercial potential as discussed in our previous article. No big pharma deal materialized, and the company raised USD45M through pre-funded warrant offerings. The drug's true upside is in systemic fungal infection; however, catalysts are expected in 2024-2025 at the earliest making the stock uninvestible at this time. We downgrade SCYX to a sell rating. Background As described in detail in our initiation of coverage, we have established an option size position on SCYX based on a potential big pharma M&A and undoubtedly cheap valuation (negative EV) of the company. However, with the recent messy financing deal (described in detail below) and lack of near-term clinical catalyst, we decided to sell out of the position and downgrade the stock. Our rationale is described below. Catalysts are expected in 2024-2025 the earliest The absence of short-term catalysts makes it un-investible for short-mid-term investors in our view. We think the major value driver of the stock is in the systemic infection space, where the catalysts are expected in 2024-2025 (as shown below). Of note, the company announced that the FDA has accepted SCYX's submission of a supplemental New Drug Application regarding label expansion of BREXAFEMME to include "prevention of recurrent vulvovaginal candidiasis" and the target PDUFA date is Nov 2022. We believe the label extension is fully priced in and any positive news will be a selling opportunity for this ticker. SCYX Homepage Messy pre-funded warrants make SCYX uninvestible in our view SCYNEXIS priced its earlier announced underwritten public offering of 3.33M shares of its common stock, prefunded warrants to purchase 11.67M shares of common stock and warrants to purchase an aggregate of 15M shares of its common stock with gross proceeds expected to be ~$45M. The shares and warrants are being sold at $3.00/share and pre-funded warrants are offered at $2.999/pre-funded warrant and accompanying warrants. Underwriters over-allotment is an additional 2.25M of shares and/or warrants to purchase up to 2.25M shares of common stock. The warrants have a seven-year term and an exercise price of $3.45/share. -Source: Seeking Alpha News April 22 The company has a long history of raising capital through messy warrants which caused the stock to tank even after the approval of Brexafemme in June 2021 (as shown below); we believe the same thing is likely to happen with any positive catalyst making the stock uninvestible. Warrants could be a catastrophe as warrant holders can start exercising their warrants and sell into the market when a stock price move above a certain level and the exercised shares were sold into the market killing the share price. SCYX data by YCharts We believe the likelihood of a potential M&A has dropped considerably at this point.
Seeking Alpha • Aug 12

SCYNEXIS Q2 2022 Earnings Preview

SCYNEXIS (NASDAQ:SCYX) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$0.59 (-168.2% Y/Y) and the consensus Revenue Estimate is $1.64M Over the last 3 months, EPS estimates have seen 2 upward revisions and 0 downward. Revenue estimates have seen 0 upward revisions and 3 downward.
Seeking Alpha • Aug 01

FDA accepts Scynexis' application to expand label for vaginal yeast infections treatment

Scynexis (NASDAQ:SCYX) on Monday said the U.S. Food and Drug Administration (FDA) had accepted the biotech's supplemental new drug application (sNDA) to expand the label of its Brexafemme tablets to include the prevention of recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis (VVC) is a type of yeast infection caused by the fungus candida which affects the vagina and the vulva. The company said the FDA had granted the sNDA submission a priority review and was set to decide on it by Nov. 30, or the so-called Prescription Drug User Fee Act date. Brexafemme is already approved to treat VVC. Recurrent VVC would be its second indication.
Seeking Alpha • Jul 19

SCYNEXIS gains after favorable data for antifungal agent in new indication

SCYNEXIS (NASDAQ:SCYX) added ~8% in the morning hours Tuesday after the commercial-stage pharma company announced promising Phase 3 data for its oral antifungal medication ibrexafungerp in patients with recurrent vulvovaginal candidiasis (RVVC). According to the data from the 24-patient CANDLE sub-study, ibrexafungerp, an FDA-authorized therapy for vulvovaginal candidiasis, has led to clinical benefits in RVVC patients who failed to respond to another antifungal therapy called fluconazole. After one day of ibrexafungerp (300 mg BID) treatment, 71% of RVVC patients (17 of 24) were found to have a significant reduction or elimination of signs and symptoms. Additionally, these results were replicated in a subset of patients who also demonstrated positive fungal cultures post-fluconazole treatment. In this 10-patient subgroup, 80% were found to have a favorable clinical response after one-day ibrexafungerp therapy. In June, SCYNEXIS (SCYX) announced the submission of its marketing application for the label expansion of ibrexafungerp in the prevention of RVVC. The supplemental New Drug Application was backed by data from the pivotal Phase 3 CANDLE, which indicated 65% clinical success for the treatment compared to ~53% for the placebo.
Article d’analyse • Apr 07

SCYNEXIS, Inc. (NASDAQ:SCYX) Analysts Just Cut Their EPS Forecasts Substantially

Today is shaping up negative for SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders, with the analysts delivering a...
Seeking Alpha • Mar 07

SCYNEXIS, Inc.: Speculative Buy, Michael Burry Sold, But I Am Buying

We are initiating Scynexis with a target price of USD 23 per share. SCYX offers an extremely attractive set up with 600% upside and limited downside (10-15%) considering its near cash. SCYX's Brexafemme is clinically de-risked and targets an attractive fungal infection space. Even though we expect muted uptake during 2022, we project 200M-400M peak sales within 5 years. The critical inflection point for the stock will be a business development activity from Big Pharma, not near-term earnings. The company has 100M cash, but has a high cash burn rate of around 50M/year and will likely need to raise 50-100M soon to fund its phase 3 trials. Considering close to cash value EV, we view BD activity as more likely and a public offering.
Article d’analyse • Feb 13

Some Analysts Just Cut Their SCYNEXIS, Inc. (NASDAQ:SCYX) Estimates

Market forces rained on the parade of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shareholders today, when the analysts downgraded...
Article d’analyse • Dec 03

Is SCYNEXIS (NASDAQ:SCYX) Using Debt In A Risky Way?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • Jul 27

Scynexis: Leading The Yeast Infection Treatment Industry

SCYNEXIS lead drug candidate BREXAFEMME recently got FDA approval for the treatment of Vulvovaginal Candidiasis, commonly known as vaginal yeast infections. BREXAFEMME is the first approved drug in the non-azole class for VVC and also the first approved drug in a novel antifungal class in the past 20+ years. The drug has ten years of market regulatory exclusivity and patent protection until 2035. The company’s financial position is robust, with adequate cash to commercialize BREXAFEMME while continuing its current studies.

Rendement pour les actionnaires

SCYXUS PharmaceuticalsUS Marché
7D11.3%5.4%1.2%
1Y0.2%44.3%28.7%

Rendement vs Industrie: SCYX a sous-performé le secteur US Pharmaceuticals qui a rapporté 44.3 % au cours de l'année écoulée.

Rendement vs marché: SCYX a sous-performé le marché US qui a rapporté 28.7 % au cours de l'année écoulée.

Volatilité des prix

Is SCYX's price volatile compared to industry and market?
SCYX volatility
SCYX Average Weekly Movement10.0%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Cours de l'action stable: SCYX n'a pas connu de volatilité de prix significative au cours des 3 derniers mois par rapport au marché US.

Volatilité au fil du temps: La volatilité hebdomadaire de SCYX ( 10% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

FondéeSalariésPDGSite web
199918David Angulowww.scynexis.com

SCYNEXIS, Inc. est une société de biotechnologie qui développe des médicaments pour le traitement et la prévention des infections fongiques difficiles à traiter et résistantes aux médicaments aux États-Unis. La société propose BREXAFEMME pour le traitement des patientes atteintes de candidose vulvovaginale et pour la réduction de l'incidence des récidives. Elle développe également le SCY-247, qui est en phase I d'essai clinique pour le traitement des infections fongiques invasives.

SCYNEXIS, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de SCYNEXIS se comparent-ils à sa capitalisation boursière ?
SCYX statistiques fondamentales
Capitalisation boursièreUS$58.10m
Bénéfices(TTM)-US$24.52m
Recettes(TTM)US$20.34m
2.9x
Ratio P/S
-2.4x
Ratio P/E

Le site SCYX est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
SCYX compte de résultat (TTM)
RecettesUS$20.34m
Coût des recettesUS$0
Marge bruteUS$20.34m
Autres dépensesUS$44.86m
Les revenus-US$24.52m

Derniers bénéfices déclarés

Mar 31, 2026

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)-0.31
Marge brute100.00%
Marge bénéficiaire nette-120.51%
Ratio dettes/capitaux propres0%

Quelles ont été les performances à long terme de SCYX?

Voir les performances historiques et les comparaisons

Analyse de l'entreprise et données financières

DonnéesDernière mise à jour (heure UTC)
Analyse de l'entreprise2026/05/26 16:43
Cours de l'action en fin de journée2026/05/22 00:00
Les revenus2026/03/31
Revenus annuels2025/12/31

Sources de données

Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.

PaquetDonnéesCadre temporelExemple de source américaine *
Finances de l'entreprise10 ans
  • Compte de résultat
  • Tableau des flux de trésorerie
  • Bilan
Estimations consensuelles des analystes+3 ans
  • Prévisions financières
  • Objectifs de prix des analystes
Prix du marché30 ans
  • Cours des actions
  • Dividendes, scissions et actions
Propriété10 ans
  • Actionnaires principaux
  • Délits d'initiés
Gestion10 ans
  • L'équipe dirigeante
  • Conseil d'administration
Principaux développements10 ans
  • Annonces de l'entreprise

* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.

Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.

Modèle d'analyse et flocon de neige

Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.

Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.

Indicateurs de l'industrie et du secteur

Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.

Sources des analystes

SCYNEXIS, Inc. est couverte par 9 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.

AnalysteInstitution
Brian Kemp DolliverBrookline Capital Markets
Corey DavisCanaccord Genuity
Liisa BaykoCitizens JMP Securities, LLC